Fiche société
NMD Pharma A/S
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| NMD670This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days. | Myasthénie | Phase 2 | À vérifier | United States, Belgium, Denmark, France, Georgia, Italy, Netherlands, Poland, … | À vérifier |
| NMD670This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days. | Myasthénie | Phase 2 | À vérifier | United States, Belgium, Denmark, France, Georgia, Italy, Netherlands, Poland, Serbia, Spain | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NMD670 | Myasthénie | Phase 2 | NCT06414954 | SYNAPSE-MG — Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||